FY2028 Earnings Forecast for Travere Therapeutics, Inc. (NASDAQ:TVTX) Issued By HC Wainwright

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for Travere Therapeutics in a note issued to investors on Wednesday, April 24th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of $4.29 for the year, down from their prior estimate of $4.66. HC Wainwright currently has a "Buy" rating and a $19.00 target price on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($3.10) per share.

TVTX has been the subject of a number of other reports. Piper Sandler lifted their target price on Travere Therapeutics from $10.00 to $11.00 and gave the stock a "neutral" rating in a report on Thursday, January 18th. Guggenheim reiterated a "neutral" rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Wedbush restated an "outperform" rating and set a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Finally, Wells Fargo & Company boosted their price objective on Travere Therapeutics from $8.00 to $9.00 and gave the company an "equal weight" rating in a report on Friday, February 16th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Travere Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Travere Therapeutics Trading Down 1.1 %

Shares of TVTX traded down $0.06 during mid-day trading on Thursday, reaching $5.39. 1,484,532 shares of the company were exchanged, compared to its average volume of 1,268,892. The stock has a market capitalization of $410.23 million, a PE ratio of -3.35 and a beta of 0.58. The business has a 50 day simple moving average of $7.34 and a two-hundred day simple moving average of $7.66. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $22.75.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.11. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The company had revenue of $45.06 million during the quarter, compared to the consensus estimate of $41.25 million.

Insiders Place Their Bets

In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of the business's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total value of $41,494.44. Following the transaction, the senior vice president now owns 80,720 shares of the company's stock, valued at $703,071.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of the business's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total value of $41,494.44. Following the sale, the senior vice president now directly owns 80,720 shares in the company, valued at $703,071.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Eric M. Dube sold 19,122 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.70, for a total value of $166,361.40. Following the completion of the sale, the chief executive officer now owns 350,600 shares in the company, valued at $3,050,220. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,773 shares of company stock valued at $300,625. Insiders own 3.75% of the company's stock.

Institutional Trading of Travere Therapeutics

Several hedge funds have recently made changes to their positions in the company. Avidity Partners Management LP bought a new position in Travere Therapeutics in the 3rd quarter worth about $11,828,000. Kynam Capital Management LP increased its stake in Travere Therapeutics by 105.6% in the 4th quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company's stock worth $17,980,000 after acquiring an additional 1,027,398 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Travere Therapeutics in the 4th quarter worth about $5,711,000. Finepoint Capital LP increased its stake in Travere Therapeutics by 60.2% in the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company's stock worth $12,904,000 after acquiring an additional 539,500 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Travere Therapeutics by 10.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company's stock worth $41,727,000 after acquiring an additional 460,176 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.